Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Kim

Showing results (21-30 of 226) with videos related to

Pageof 23
Sort By:
Pharmacogenomics|October 4, 2013
Sunny outlook for personalized medicine: tamoxifen and beyondWendy A Teft, Richard B Kim
Drug Metabolism and Pharmacokinetics|October 11, 2012
Impact of genetic variation in OATP transporters to drug disposition and responseInna Y Gong, Richard B Kim
Critical Reviews in Clinical Laboratory Sciences|September 3, 2014
Is personalized medicine a dream or a reality?Bridget L Morse, Richard B Kim
The Canadian Journal of Cardiology|June 25, 2013
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixabanInna Y Gong, Richard B Kim
Expert Opinion on Drug Metabolism & Toxicology|September 17, 2016
Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkersAdrienne E Borrie, Richard B Kim
Personalized Medicine|May 23, 2018
Personalized medicine: importance of clinical interpretative skills for real-world patient careSteven E Gryn, Richard B Kim
Clinical Pharmacology and Therapeutics|September 13, 2005
Transporters and drug therapy: implications for drug disposition and diseaseRichard H Ho, Richard B Kim
Hepatology (Baltimore, Md.)|September 30, 2009
Hepatic drug transporters, old and new: pharmacogenomics, drug response, and clinical relevanceMarianne K DeGorter, Richard B Kim
European Heart Journal|July 30, 2009
Personalized medicine and antiplatelet therapy: ready for prime time?Céline Verstuyft, Tabassome Simon, Richard B Kim
Annals of Internal Medicine|August 4, 2020
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case ReportEugene Brailovski, Richard B Kim, David Juurlink
Pageof 23

Showing results (21-30 of 226) with videos related to

Sort By:
Pageof 23
Pharmacogenomics|October 4, 2013
Sunny outlook for personalized medicine: tamoxifen and beyondWendy A Teft, Richard B Kim
Drug Metabolism and Pharmacokinetics|October 11, 2012
Impact of genetic variation in OATP transporters to drug disposition and responseInna Y Gong, Richard B Kim
Critical Reviews in Clinical Laboratory Sciences|September 3, 2014
Is personalized medicine a dream or a reality?Bridget L Morse, Richard B Kim
The Canadian Journal of Cardiology|June 25, 2013
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixabanInna Y Gong, Richard B Kim
Expert Opinion on Drug Metabolism & Toxicology|September 17, 2016
Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkersAdrienne E Borrie, Richard B Kim
Personalized Medicine|May 23, 2018
Personalized medicine: importance of clinical interpretative skills for real-world patient careSteven E Gryn, Richard B Kim
Clinical Pharmacology and Therapeutics|September 13, 2005
Transporters and drug therapy: implications for drug disposition and diseaseRichard H Ho, Richard B Kim
Hepatology (Baltimore, Md.)|September 30, 2009
Hepatic drug transporters, old and new: pharmacogenomics, drug response, and clinical relevanceMarianne K DeGorter, Richard B Kim
European Heart Journal|July 30, 2009
Personalized medicine and antiplatelet therapy: ready for prime time?Céline Verstuyft, Tabassome Simon, Richard B Kim
Annals of Internal Medicine|August 4, 2020
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case ReportEugene Brailovski, Richard B Kim, David Juurlink
Pageof 23